| Sabena Toor, MD | |
|
8635 W 3rd St Ste 355w, Los Angeles, CA 90048-6112 | |
| (310) 967-3075 | |
| (310) 652-9133 |
| Full Name | Sabena Toor |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 35 Years |
| Location | 8635 W 3rd St Ste 355w, Los Angeles, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013097088 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | G71637 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cedars-sinai Medical Center | Los angeles, CA | Hospital |
| Entity Name | Sabena Toor A California Professional Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265563027 PECOS PAC ID: 6800967589 Enrollment ID: O20080624000593 |
News Archive
BioMimetic Therapeutics, Inc. today announced that it has received orphan drug designation from the Food and Drug Administration for its protein therapeutic, recombinant human platelet derived growth factor, to be used in conjunction with autograft and/or commercially available osteochondral allograft for the treatment of osteochondritis dissecans of the knee, elbow or ankle.
A study by the UPV/EHU has found that undocumented immigrants encounter structural and individual barriers linked to their social vulnerability when accessing public health services in the Basque Autonomous Community.
A new analysis of blood sera taken from 63 COVID-19 patients, 71 controls, and various coronavirus-exposed animals provides strong support for the use of the SARS-CoV-2 virus' receptor-binding domain (RBD) as an antigen for reliable tests to detect antibodies to the virus.
A five per cent difference in favor of the 48 hours. This is the result of a study from Aarhus University that has spent several years examining the possible benefits of cooling down patients suffering cardiac arrest to 33°C for 48 hours, instead of the 24-hours that is standard practice in most places.
The Biotechnology Industry Organization (BIO) today announced the launch of BIO Ventures for Global Health (BVGH), a new nonprofit organization that will work to enlist the biotechnology industry in the fight against neglected diseases. BVGH has received a $1 million start-up grant from the Bill & Melinda Gates Foundation.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sabena Toor, MD 8635 W 3rd St Ste 355w, Los Angeles, CA 90048-6112 Ph: (310) 967-3075 | Sabena Toor, MD 8635 W 3rd St Ste 355w, Los Angeles, CA 90048-6112 Ph: (310) 967-3075 |
News Archive
BioMimetic Therapeutics, Inc. today announced that it has received orphan drug designation from the Food and Drug Administration for its protein therapeutic, recombinant human platelet derived growth factor, to be used in conjunction with autograft and/or commercially available osteochondral allograft for the treatment of osteochondritis dissecans of the knee, elbow or ankle.
A study by the UPV/EHU has found that undocumented immigrants encounter structural and individual barriers linked to their social vulnerability when accessing public health services in the Basque Autonomous Community.
A new analysis of blood sera taken from 63 COVID-19 patients, 71 controls, and various coronavirus-exposed animals provides strong support for the use of the SARS-CoV-2 virus' receptor-binding domain (RBD) as an antigen for reliable tests to detect antibodies to the virus.
A five per cent difference in favor of the 48 hours. This is the result of a study from Aarhus University that has spent several years examining the possible benefits of cooling down patients suffering cardiac arrest to 33°C for 48 hours, instead of the 24-hours that is standard practice in most places.
The Biotechnology Industry Organization (BIO) today announced the launch of BIO Ventures for Global Health (BVGH), a new nonprofit organization that will work to enlist the biotechnology industry in the fight against neglected diseases. BVGH has received a $1 million start-up grant from the Bill & Melinda Gates Foundation.
› Verified 3 days ago
Dr. Linda Fong, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6041 Cadillac Ave, Los Angeles, CA 90034 Phone: 323-857-3290 | |
Dr. Robert Peter Gale, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 11693 San Vicente Blvd, Suite 335, Los Angeles, CA 90049 Phone: 310-442-9010 | |
Dr. Tarek Alasil, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8616 La Tijera Blvd Ste 404, Los Angeles, CA 90045 Phone: 310-673-2020 Fax: 310-469-5290 | |
David Michael Tellalian, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8635 W 3rd St Ste 465w, Los Angeles, CA 90048 Phone: 310-358-2300 Fax: 310-358-2308 | |
Dr. Jan B King, M.D., M.P.H. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 11833 Wilmington Ave Fl 2, Los Angeles, CA 90059 Phone: 323-568-8701 | |
Dr. Caroline Hwang, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1520 San Pablo St, Suite 1000, Los Angeles, CA 90033 Phone: 323-442-5100 | |
Dr. Jennifer A Fulcher, M.D., PH.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 10833 Le Conte Ave, Chs 37-121, Los Angeles, CA 90095 Phone: 310-825-7225 |